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Abstract
Background: Intrauterine balloon aortic valvuloplasty (IUBAV) has been used for critical aortic stenosis. However, it
is necessary to determine the fetal impairments such as preterm birth after this approach and to find a way to
prevent or reduce them.
Methods: In the present study, we evaluated the therapeutic value of indomethacin (IDM) and dexamethasone
(DXS) on reducing the preterm birth rate in experimental goats after IUBAV.
Results: Our results indicated that the administration of IDM/DXS significantly reduced the rate of premature birth.
IDM/DXS treatment led to preservation of myocardial ultrastructure with less damage, and amelioration of the fetal
and placental circulation. Furthermore, we found that norepinephrine (NE) level was positively associated with the
degree of myocardial damage. IDM/DXS administration led to a significant decrease of operation-induced increase
of NE levels, which may be associated with the protective effects of IDM/DXS. Lastly, we found that the
administration of IDM/DXS did not induce the risk of ductus arteriosus closure or slow down fetal growth.
Conclusions: Our results indicate that IDM/DXS promotes a better gestational outcome at least partially by
reducing stress response during and after the operation of IUBAV in the goat model. IDM/DXS may be a useful
application in human patients during IUBAV intervention.
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Background
Most severe congenital heart defects have a poor progno-
sis if intervention is not received. Prenatal diagnosis and
intervention of certain defects may correct the primary
lesion and subsequently prevent the secondary lesions
[1-6]. Several studies have demonstrated that the surgical
techniques can ensure the mother’s safety in most cases
[7-12]. Recently, ultrasound-guided intervention has
been introduced to the surgery of intrauterine cardiac
intervention (IUCI), which allows the intervention to be
achieved without opening of uterus and establishing
extracorporeal circulation [7-14].
Since the first report of intrauterine balloon aortic val-
vuloplasty (IUBAV) in 1991 [10], several groups have
published their studies of prenatal cardiac interventions
for aortic valve stenosis [7-13]. In these cases, the access
to the fetal heart has been achieved by a direct
ultrasound-guided strategy. However, even with success-
ful intervention, fetal impairments induced by the novel
approach are still unclear [7,13]. Recently, we established
an experimental goat model of IUBAV and evaluated the
operation-induced fetal metabolic and hemodynamic
change, stress response, histological change in critical
organs, as well as mother’s safety and gestation out-
comes in the fetal and mother goats [15]. We found that
the IUBAV operation had significant and immediate
* Correspondence: nathan_hua@163.com
1Department of Pediatric Cardiology, Second University Hospital and West
China Medical School, Sichuan University, Chengdu 610041, China
5Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth
Defects of Ministry of Education, Second University Hospital and West China
Medical School, Sichuan University, Chengdu 610041, China
Full list of author information is available at the end of the article
© 2012 Zhou et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Zhou et al. Journal of Biomedical Science 2012, 19:74
http://www.jbiomedsci.com/content/19/1/74
impact on the fetus and induced a strong stress re-
sponse, which might not cause pathological changes in
critical organs, but might disrupt the continuation of
normal gestation in the long term.
We hypothesized that successful control of uterine
contraction and suppress of stress response may en-
hance the post-procedure fetal states. Since indometh-
acin (IDM) can reduce uterine contraction and has been
used to prevent preterm birth [16,17] and dexametha-
sone (DXS) is used to inhibit stress responses and also
increases microvillous membrane formation of the newly
generated syncytial layer, which may increase fetal
growth, prevent preterm labor, and help the continu-
ation of affected pregnancy [18,19], in the present study,
we tested our hypothesis by evaluating the therapeutic
value and potential risk of IDM and DXS in a goat
model with IUBAV.
Methods
Animal and experimental group
Thirty-two pregnant goats with twin gestation in 2nd-
and 3rd- trimester [112–123 days (term: 150 days),
weight, 36.5–44.0 kg] and fifteen normal female goats
without pregnancy (weight, 29.5–41.0 kg) were pur-
chased from Daye Livestock & Poultry Farms (Ziyang,
Sichuan). This study was completed in accordance with
the guidelines on the care and use of animals for re-
search purposes by the Animal Care and Use Committee
of Sichuan University.
Pregnant goats were used to study the therapeutic
value of IDM and DXS to control preterm delivery and
its risk (Preterm birth was defined as birth before 135
gestational days). The gestational age and body weight of
fetuses were estimated on the basis of pregnant date and
further confirmed by measuring biparietal diameter
(BPD) and femur length (FL). According to the treat-
ment, these goats were divided into control and treat-
ment groups (A and B groups, n = 16/group). The
control group received placebos and treatment group
received indomethacin (IDM, orally, 1.5-2 mg/kg/day)
starting at 7 days before operation, and dexamethasone
(DXS, intracardial injection into left ventricle, 1 mg/kg)
during the IUBAV process. The fetus on the right side of
mother abdomen was selected to receive IUBAV, and
the one on left side served as control. Accordingly,
fetuses were respectively defined as IUBAV and control
groups (n = 16/group).
According to the combination of treatment and oper-
ation, the fetal goats were named as “no treatment con-
trol without IUBAV (A-c)”, “no treatment but with
IUBAV operation (A-o)”, “treatment control without
IUBAV operation (B-c)” and “treatment with IUBAV op-
eration (B-o)”. The baseline of the enrolled fetuses was
similar in the four groups, which included gestational
day [d, mean ± SEM, 109.33 ± 1.99(A-c), 112.35 ± 2.61
(A-o), 107.66 ± 2.36(B-c), and 110.94 ± 2.94(B-o) re-
spectively, p =0.196], biparietal diameter (mm, mean ±
SEM, 42.36 ± 1.08, 45.51 ± 1.19, 44.21 ± 1.41, and 44.79
± 0.99 respectively, p = 0.071), and aorta diameter (mm,
mean ± SEM, 6.10 ± 0.13, 6.35 ± 0.16, 6.15 ± 0.15, 6.25
± 0.15 respectively, p = 0.357). Eight pregnant goats (4
from A and 4 from B group) underwent Cesarean sec-
tion (C-section) at 3 hour after the operation. Another
eight pregnant goats (4 from A and 4 from B group)
underwent Cesarean section (C-section) 3 days after op-
eration. Hearts from those fetuses were collected. Two
samples from each heart were taken from left ventricular
front wall and muscular septum. Tissues were fixed with
glutaraldehyde followed by osmium tetroxide. After
being washed with PBS, the tissues were dehydrated in
alcohol series, embedded in epoxy resin, sectioned at a
thickness of 70 nm, stained with uranyl acetate and lead
citrate. The resultant sections were subjected to examin-
ation for ultrastructure using a transmission electron
microscope (H-7650, Hitachi, Japan).
Mitochondrial damage was assessed using FLAMENG
grading system [20]: 0 = normal matrix granules without
visible damage; 1 = loss of matrix granules and light
clearing of matrix; 2 = moderate clearing of matrix,
moderate swelling, and partial fragmentation of cristae;
3 = severe clearing, severe swelling, loss of cristae; and 4
= amorphous dense granules. Mitochondrial damage
was examined at 5 microscopic fields for each tissue sec-
tion. The average of the mitochondrial damage grading
was used as damage index.
In the study on the effect of exogenous norepinephrine
(NE) on myocardial ultrastructure in normal goats, sa-
line or NE was intravenously infused to five groups of
anesthetized goats (n = 3) at a dose of 1, 5, 10 and
30 μg/ kg/min for one hour (which was based on one-
hour IUBAV operation), respectively, and accordingly
named as control group (saline), NE1, NE5, NE10 and
NE30. The blood samples were collected before the infu-
sion, at 15, 30, 45, and 60 minutes following the initi-
ation of infusion, as well as 30, 60, 120, and 180 minutes
after the completion of infusion. Hearts were collected
from the control, NE1, NE5 and NE10 groups 3 hours
after the completion of NE infusion. All goats in NE30
group showed serious ventricular arrhythmias and were
sacrificed when life-ending signs were observed. Hearts
of goat of NE30 group were collected about 30 min after
completion of NE infusion.
Surgery
The goats were prepared as previously reported [15].
Briefly, pregnant goats were fasted for 36 hours, forbid-
den from drinking for 12 hours and anesthetized using
Atropine (i.m., 0.03–0.05 mg/kg), Ketamine (i.m.,
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10 mg/kg), diazepam (i.v.p., 0.5–1 mg/kg) and infusion
of 2.5% chloralhydrate (35–50gtt/min). Ketamine was
added (3 mg/kg) every one hour. Diazepam (i.v.p., 0.3–
0.5 mg/kg) was given when necessary. The fetus was
sedated and anesthetized through the placental circula-
tion plus intramuscular injection of Ketamine (10 mg/
kg). During the entire surgery, mother goats were main-
tained with a spontaneous respiration and were sup-
ported with 40–60% oxygen and Ringer solution. Fetuses
and mothers were monitored under ultrasound and elec-
trocardiogram, respectively.
For the IUBAV operation, pregnant goats were placed
in the supine position, following skin preparation and the
abdominal wall was opened to expose part of uterus
under aseptic conditions. With the continuous guidance
of ultrasound (Mindray M5 color Diagnostic Ultrasound
System, China), an appropriate puncture site and ultra-
sonic plane was selected. A trocar with 4 F hemostatic
sheath and 18 gauge puncture needle (PTC-B, Hakko
Co., Ltd., Japan) was introduced through the uterine wall,
fetal chest wall, and into the fetal left ventricle (LV). The
puncture needle was placed in the direction of blood
flow. After the core needle was pulled out, a coronary
guide wire (0.014 in, Abbott, Ltd., USA) was inserted
until it reached the descending aorta. Following the guide
wire, hemostatic core and sheath were inserted into the
LV. Finally, the hemostatic core was pulled out and
replaced with a balloon catheter (5–7.0 mm×15 mm,
Tyshak II NuMED, Inc., USA). The balloon was dilated 2
times at the level of the aortic annulus. The blocking
time of blood flow in each balloon expansion was ap-
proximately 2 seconds. The control fetuses did not
undergo the puncture and cardiac intervention. The total
time from anesthesia to the close of the abdominal open-
ing was about 1.5-2 hours. Lincomycin hydrochloride
was intravenously infused (20 mg/kg) to mother goats
intraoperatively and also used for intraperitoneal (1.2 g/
goat) rinse at the end of the surgery plus postoperative
administration (10 mg/kg/day for 7 days). Left ventricular
systolic pressure (LVSP) was measured through puncture
needle or trocar at different time points, with an exten-
sion tube connected to pressure monitor (Mindray PM-
7000 portable multi parameter monitor, China).
Sample collection and data analysis
Based on our previous study, the following five time
points were chosen in the current study: before IUBAV
(the time after the needle successfully was inserted into
the heart but before the dilation of balloon, named as
“Pre”), after IUBAV (after the operation was completed,
named as “Post”), 3 hours and 3 days post-operation
(namely, 3 h-post and 3d-post, respectively), and 24
hours after birth (named as Neo). The data for heart
rate, ratio of peak blood flow between systolic and
diastolic phase (S/D) of aorta and umbilical artery, diam-
eter and blood flow peak velocity in ductus arteriosus
were obtained from echocardiographic results. Left ven-
tricular systolic pressure (LVSP) for operated fetus was
measured through balloon catheter during IUBAV oper-
ation. For control goats, cardiac puncture with PRC-B
18-20 G (Hakko Co., Ltd., Japan) was performed, and
LVSP was recorded via a biomedical recording system
(PM-8000 Mindray, Shenzhen, China). Serum from fetus
or normal adult goat were collected at designated time
points and subjected to measurement of NE concentra-
tion using routine clinical sample analysis method and
procedure.
Statistical analysis
The SPSS program software (version 13.0, SPSS Inc.,
USA) was used for statistical analysis. Quantitative data
were expressed as Mean ± SEM. One way ANOVA was
used to analyze the difference among groups and Fisher
Exact Test was used for two group comparisons. The
differences were considered significant when p <0.05.
Results
IDM/DXS treatment reduced the rate of preterm delivery
following IUBAV operation
To determine whether IDM/DXS is beneficial for the
improvement of the gestation outcome following IUBAV,
we monitored both treatment and control groups of
pregnant goats up to the time of natural delivery. In
contrast to 50% (4 of 8) preterm delivery in the pregnant
goats that did not receive IDM/DXS treatment, only
12.5% (1 out 8) preterm delivery was observed in the
pregnant goats received IDM/DXS treatment (Figure 1).
IDM/DXS treatment ameliorated hemodynamic during
and after IUBAV
To evaluate whether IDM/DXS treatment impacts the
fetal hemodynamic response to the operation, we mea-
sured heart rate, left ventricular systolic pressure (LVSP),
ratio of peak blood flow at systolic and diastolic phase
(S/D) of aorta and umbilical artery, diameter and blood
flow peak velocity in ductus arteriosus at designated
time points (Figure 2 and Tables 1, 2, 3 and 4). As
shown in Table 1, the operation induced a significant in-
crease of heart rate compared to the preoperational
levels in all fetuses either immediately (time point: Post)
or 3 days post operation. IDM/DXS administration alone
did not alter the HR (group B). LVSP was decreased at
the time of IUBAV completion compared to the preo-
perational levels in both control and IDM/DXS groups
(Table 2). The decreased LVSP returned to the baseline
3 hours after the operation. However, the LVSP in IDM/
DXS group with IUBAV (B-o group) was higher than
that in the group without IDM/DXS treatment but with
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IUBAV (A-o), and a quicker return of LVSP to baseline
was revealed, which might be caused by IDM/DXS treat-
ment. Aortal S/D in goat fetuses was significantly
increased in both groups with or without IUBAV and it
did not return to the preoperational level until 3 days
after the operation (denoted by * in Table 3). Noticeably,
the increase of aortal S/D in fetuses with IUBAV (group
A-o and B-o) showed a greater extent than that in the
counterpart twins without IUBAV (groups, A-c, and B-
c), and this difference was detected at the time of IUBAV
completion and 3 hour post operation (denoted by p1
and p2, respectively, in Table 3). Encouragingly, IDM/
DXS administration appears to inhibit the aortal S/D in-
crease in fetuses from both groups with or without
IUBAV (denoted by p3, and p4, respectively, in Table 3),
and this effect was also shown at the time of IUBAV
completion and 3 hour post operation. Consistently, um-
bilical artery S/D of goat fetuses showed the same
change pattern as aortal S/D following IUBAV and IDM/
DXS treatment (Table 4), suggesting that IDM/DXS
treatment significantly ameliorated both fetal and pla-
cental circulation.
Myocardial ultrastructure change following IUBAV with or
without IDM/DXS treatment
To further evaluate the impact of IUBAV on heart struc-
ture and function, we examined the ultra structure of
the heart using an electron microscope in fetuses from
four groups 3 hours and 3 days after the operation
(Figure 3). The myocardial damages were analyzed
based on the myocardial and mitochondria morpho-
logical changes [20]. As shown in Figure 3, myocardial
vacuolization, degranulation of endoplasmic reticulum,
and mitochondria damages were observed in the fetal
Figure 1 Administration of IDM/DXS decreased the rate of
preterm delivery following IUBAV operation. Two groups of
pregnant goats received IUBAV were daily monitored up to the time
of natural delivery. The preterm birth rate was calculated in control
(group A without IDM/DXS treatment, empty bar) and IDM/DXS
treated groups (group B, black bar).
Figure 2 Hemodynamic measurements on experimental animals with ultrasound. Upper panel: representative echocardiographic results
showing blood flow and S/D in fetal aorta (A) and umbilical artery (B). Lower panel: representative spectrum of blood flow in ductus arteriosus of
fetus without (C) or with (D) IDM/DXS treatment.
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hearts of four groups with a varied extent. Statistical
comparisons revealed that significant differences existed
between fetuses with IUBAV and fetuses without
IUBAV (A-o vs. A-c, and B-o vs. B-c in Figure 3B) 3
hours after the operation. However, these differences
were not detected on fetuses 3 days post-operation,
suggesting that myocardial damage at ultrastructure
level was reversible (Figure 3A low panel and 3C).
IDM/DXS treatment reduced fetal NE level
Our previous study [15] revealed that fetal NE level was
remarkably increased following IUBAV. Since NE has
various effects on hemodynamics, we further determined
whether IDM/DXS treatment could change the level and
acting time of fetal serum NE after IUBAV operation. As
shown in Table 5, while NE levels in fetuses with IUBAV
was significantly higher than the preoperational level in
both A-o and B-o groups at the time of IUBAV comple-
tion, 3 hours, and 3 days post operation, the magnitude
of the NE increase was significantly less in IDM/DXS
treatment groups (group B-o vs. A-o). And the duration
of elevated NE was shorter in IDM/DXS groups than
that in control groups. These results suggested that one
of the beneficial effects of IDM/DXS was to control NE
level and to reduce stress response and shorten NE act-
ing time.
Myocardial ultrastructure change was associated with the
level of NE
It has been reported that high level of NE results in
myocardial damage [21-23]. To assess the relationship
between NE and myocardial damage in our goat model,
we examined the myocardial ultrastructure and damage
in five groups of the normal goats (n = 5) receiving infu-
sion of NE at a variety of concentrations. As shown in
Figure 4, exogenous infusion of NE led to an increase of
serum NE level; and the artificial increase of NE level
was correlated to the extent of the myocardial damage
in a dose-dependent manner. In addition, fetal NE level
and myocardial damage following IUBAV were compar-
able with the features of NE1 and NE5, especially closed
to NE1, which were at low level and would result revers-
ible damage in vitro and in vivo experiments.
Evaluation of the safety of IDM/DXS administration in
short- and long-terms
Since indomethacin has been used to promote closure of
ductus arteriosus in pre-term newborns, which could be
one side effect if used in the IUBAV [16,24], we further
measured diameter and blood flow peak velocity in
ductus arteriosus of goat fetuses to determine this effect
of indomethacin. As shown in Table 6, the diameter and
blood flow velocity of ductus arteriosus did not show
significant difference among the fetuses from the four
groups. Furthermore, we compared the body weight
(BW) and hematocrit (Hct) among the full-term neo-
nates from treated and untreated group with IDM/DXS,
to determine the impact of IDM/DXS on development
and growth. The parameters including Body weight
[BW, kg, 2.36 ± 0.11 (A-c), 2.33 ± 0.13 (A-o), 2.34 ±
0.07 (B-c), 2.39 ± 0.12 (B-o) respectively, p = 0.806] and
hematocrit (Hct, 0.38 ± 0.02, 0.39 ± 0.02, 0.41 ± 0.02,
Table 1 Heat rate of goat fetuses and neonates before and after operation (mean ± SEM)
Group Pre(n = 16) Post(n = 16) 3 h-Post(n = 16) 3d-Post(n = 12) Neo▲
A-c 136 ± 5 197 ± 7* 188 ± 5*# 165 ± 6*#} 124 ± 10
A-o 144 ± 6 206 ± 6* 191 ± 9*# 168 ± 6*#} 119 ± 11
B-c 138 ± 4 188 ± 8* 175 ± 6*# 158 ± 8*#} 126 ± 11
B-o 135 ± 6 196 ± 7* 183 ± 7*# 161 ± 6*#} 127 ± 8
p 0.163 0.067 0.085 0.112 0.125
*significant difference compared to Pre, #significant difference compared to Post, }significant difference compared to 3 h-Post; ▲n = 4 in groups A-c and A-o; n = 7
in groups B-c and B-o.
Table 2 Left ventricular systolic pressure of goat fetus and neonates (mmHg) (mean ± SEM)
Group Pre Post 3 h-Post 3d-Post Neo▲
(n = 16) (n = 16) (n = 4) (n = 4)
A-c – – 27.36 ± 1.66 25.92 ± 1.61 56.17 ± 2.98
A-o 24.32 ± 0.63 19.61 ± 1.04* 22.34 ± 1.33# 26.11 ± 2.31# 58.92 ± 3.39
B-c – – 27.62 ± 2.12 27.73 ± 1.87 63.13 ± 2.19
B-o 26.24 ± 0.84 23.51 ± 0.49*} 25.37 ± 1.98#} 25.47 ± 1.43# 59.45 ± 1.87
p 0.072 0.003 0.026 0.087 0.127
*significant difference compared to Pre; #significant difference compared to Post; }significant difference compared to A-o; – = not measured; ▲n = 4 in groups A-c
and A-o; n = 7 in groups B-c and B-o. p <0.05 is given in bold.
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and 0.40 ± 0.02 respectively, p = 0.749) of full-term neo-
nates (mean ± SEM), no significant differences were
detected. These data suggest that IDM/DXS at adminis-
tered dose in the current study can promote a better
gestational outcome without introducing risk of ductus
arteriosus closure or delaying fetal growth.
Discussion
Intrauterine intervention for certain congenital heart
defects, such as obstruction, may prevent the progres-
sion of the severity of the primary lesions and the de-
velopment of secondary lesions [7-12]. Although the
technical feasibility has been achieved in animal models as
well as in clinical patients [13,25-28], the selection of the
right patients in consideration of the long-term outcome
of the fetus is still controversial. Our recent study [15]
indicated that the IUBAV operation itself causes signifi-
cant stress responses in fetuses of a goat model, which may
in turn disrupt the normal course of gestation. Therefore,
we extended our study to determine whether the combina-
torial application of contraction inhibitor, indomethacin,
and stress inhibitor, dexamethasone, could improve the
gestational outcome. Furthermore, we tried to explore the
protective effects of IDM/DXS on hemodynamics, myo-
cardial ultrastructure, and stress response, which are not
well addressed in human patients due to ethical concerns.
In the current study, we obtained several important
findings. First, the administration of IDM/DXS signifi-
cantly reduces the rate of premature birth. Second,
IDM/DXS treatment leads to a preservation of myocar-
dial ultrastructure with less damage and an amelior-
ation of the fetal and placental circulation. Third,
administration of IDM/DXS significantly decreases
IUBAV operation-induced elevation of NE levels, which
might be associated with myocardial ultrastructure
changes, since the NE level is positively related with
the degree of myocardial damages. Lastly, IDM/DXS at
the dose that we used in our study can promote a bet-
ter gestational outcome without introducing risk of
ductus arteriosus closure or delaying fetal growth. Col-
lectively, our data suggest that administration of IDM/
DXS promotes a better gestational outcome by amelior-
ating fetal hemodynamic and reducing myocardial
damages caused by IUBAV operation.
As a nonspecific inhibitor of cyclooxygenase (COX),
indomethacin is capable of reducing uterine contraction
by blocking the synthesis of prostaglandin (PG). It has
been widely used as an agent to control premature birth
[16,17]. In addition to its contraction-inhibiting effects,
our study also shows that IDM is capable of reducing
the operation-induced hemodynamic fluctuation in
fetuses, which is consistent with other studies [29,30].
Table 3 Aortic S/D of goat fetus and neonates (mean ± SEM)
Group Pre(n = 16) Post(n = 16) 3 h-Post(n = 16) 3d-Post(n = 12) Neo ▲
A-c 2.31 ± 0.08 2.87 ± 0.06* 2.59 ± 0.07*# 2.44 ± 0.04# 2.19 ± 0.12
A-o 2.45 ± 0.06 3.44 ± 0.08* 3.11 ± 0.06*# 2.37 ± 0.06#} 2.36 ± 0.12
p1: 0.165 0.0001 0.0001 0.344 0.035
B-c 2.39 ± 0.07 2.69 ± 0.06* 2.34 ± 0.03# 2.33 ± 0.06# 2.25 ± 0.06
B-o 2.49 ± 0.06 3.01 ± 0.09* 2.88 ± 0.05*# 2.53 ± 0.07#} 2.33 ± 0.07
p2 0.477 0.007 0.0001 0.021 0.42
p3 0.453 0.031 0.002 0.131 0.713
p4 0.631 0.002 0.003 0.069 0.829
*significant difference compared to Pre; #significant difference compared to Post; }significant difference compared to 3 h-Post; p1: A-o vs. A-c; p2: B-o vs. B-c; p3:
B-c vs. A-c; p4: B-o vs. A-o. ▲n = 4 in groups A-c and A-o; n = 7 in groups B-c and B-o. p <0.05 is given in bold.
Table 4 Umbilical artery S/D of goat fetus and neonate (mean ± SEM)
Group Pre(n = 16) Post (n = 16) 3 h-Post(n = 16) 3d-Post(n = 12) Neo▲
A-c 2.21 ± 0.03 2.44 ± 0.06* 2.59 ± 0.06* 2.46 ± 0.04* 1.94 ± 0.11
A-o 2.25 ± 0.05 3.11 ± 0.07* 2.87 ± 0.04*# 2.67 ± 0.04*#} 2.15 ± 0.08
p1 0.512 0.0001 0.001 0.001 0.07
B-c 2.09 ± 0.06 2.55 ± 0.05* 2.54 ± 0.05* 2.23 ± 0.06 2.11 ± 0.06
B-o 2.11 ± 0.05 2.83 ± 0.05* 2.65 ± 0.07*# 2.56 ± 0.06*# 2.08 ± 0.07
p2 0.746 0.001 0.541 0.001 0.727
p3 0.071 0.034 0.066 0.002 0.153
p4 0.063 0.002 0.016 0.936 0.516
*significant difference compared to Pre; #significant difference in contrast to Post; }significant difference compared to 3 h-Post; p1: A-o vs. A-c; p2: B-o vs. B-c; p3:
B-c vs. A-c; p4: B-o vs. A-o. ▲n = 4 in groups A-c and A-o; n = 7 in groups B-c and B-o. p <0.05 is given in bold.
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Dexamethasone is a synthetic corticosteroid widely used
in serious or emergency situations, including surgery
[18,19]. Because it enables the body to overcome stress
by increasing the heart rate and contractility, leading to
an increase of blood supply to essential organs, DXS was
intracardially injected along with the application of indo-
methacin in the present study. We did not observe any
side effects related to the administration of IDM/DXS
under our study conditions. While we thought that the
observed beneficial effects were derived from reduction
of uterine contraction and decrease of stress responses,
we can not exclude other mechanisms of the two agents
that may be involved in inhibiting the production of
other labor-initiating factors. For example, both IDM
and DXS possess anti-inflammatory and immunosup-
pressive properties, which may contribute to the control
Figure 3 Myocardial ultrastructure of goat fetuses without or with IDM/DXS treatment. A: Representative micrographs of four groups of
goat fetal myocardial tissues (×24000) at 3 hours (upper panel) and 3 days (lower panel) post operation. B: Quantitative results of mitochondrial
damage at 3 hours post operation. C: Quantitative results of mitochondrial damage at 3 days post operation.
Table 5 Fetal serum NE concentration before, during and after IUBAV operation in the presence and absence of IDM/
DXS treatment ( mean ± SEM )
Group Pre (n = 16) Post (n = 16) 3 h-Post (n = 4) 3d-Post (n = 4)
A-c – – 4515.91 ± 182.94 2251.22 ± 100.85 }
A-o 1633.45 ± 61.87 9921.29 ± 223.68* 6436.81 ± 282.85 *# 3133.58 ± 98.18 *#}
B-c – – 3628.33 ± 194.56 2128.64 ± 132.35 }
B-o 1542.08 ± 49.81 8246.54 ± 283.86* 4792.31 ± 389.67 *# 2098.35 ± 134.48 *#}
p1 n/a n/a 0.009 0.001
p2 n/a n/a 0.001 0.725
p3 n/a n/a 0.017 0.487
p4 0.356 0.001 0.015 0.001
*significant difference compared to Pre; # significant difference compared to Post; }significant difference compared to 3 h-Post; – = not measured; n/a = not
applicable; p1: A-o vs. A-c; p2: B-o vs. B-c; p3: B-c vs. A-c; p4: B-o vs. A-o. p <0.05 is given in bold.
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of inflammatory responses to the tissue damage during
operation and ultimately reduce the level of inflamma-
tory mediators that may promote the labor initiation. In
addition, IDM readily crosses the placenta and can re-
duce fetal urine production and the amount of amniotic
fluid. DXS also increases microvillous membrane forma-
tion of the newly generated syncytial layer and thus facil-
itates the continuation of affected pregnancy [18,19]. In
summary, the exact mechanisms underlying the benefi-
cial effects of IDM/DXS treatment after IUBAV remain
to be elucidated by further investigation.
It is well known that catecholamines have a variety of
effects on cardiovascular system, depending on their
concentration and acting time [31]. While it promotes
myocardial hypertrophy and regulates vascular resistance
at a low concentration, NE can cause myocardial apop-
tosis and necrosis at a high concentration both in vitro
and in vivo [32,33]. Although fetuses during the IUBAV
operation are anesthetized through the placental circula-
tion, their stress responses are still significant and the
“catecholamine storm” can directly result in the
impairment of myocardial ultrastructure. To test this
possibility, we conducted an experiment that was specif-
ically designed to determine the relationship between
serum NE levels and myocardial ultrastructure. Consist-
ently, we observed a similar myocardial damage after in-
fusion of exogenous NE. It strongly suggests that
IUBAV-induced release of endogenous NE might be, at
least partially, responsible for the myocardial damages in
fetal hearts after IUBAV operation.
Through comparison, we found that fetal NE level and
myocardial damage in IUBAV were comparable with
that of infused exogenous NE at low level. The IUBAV-
induced fetal myocardial damage seems to be transient
and reversible without intervention. IDM/DXS treat-
ment can significantly reduce the magnitude of the
increased NE level, reduce the degree of myocardial
damages and shorten the acting time of NE after IDM/
DXS treatment. Although all the changes following
IUBAV were combination effects by multiple factors, we
only selected a representative index (NE) to research, be-
cause the direction and level of NE were well consistent
Figure 4 The relationship between NE level and myocardial damage. A: Starting from the initiation of intravenous infusion of saline or NE,
goat blood samples were collected during (T0-T60) and after infusion (A-T30-180) at designated time points. Serum samples were subjected to
measurement of NE level and each group was plotted in a curve (Con = saline, NE group was named according to the infused NE concentration.
This group name is applicable for subfigure B and C). B: Representative micrographs of myocardial tissue of goats at 3 hours after the completion
of NE for groups, Con, NE1, NE5 and NE10; at 30 min after NE infusion for group NE30 (×24000). C: Quantitative results of mitochondrial damage
as observed in B.
Table 6 Diameter (D) and blood flow peak velocity (V) in ductus arteriosus of goat fetuses (mean ± SEM)
Group Pre-treatment (n = 16) Pre-procedure (n = 16) 3d-Post procedure(n = 12)
D(mm) V(m/s) D(mm) V(m/s) D(mm) V(m/s)
A-c 3.12 ± 0.11 1.06 ± 0.03 3.11 ± 0.06 1.14 ± 0.05 3.19 ± 0.11 1.12 ± 0.04
A-o 2.96 ± 0.11 1.13 ± 0.04 3.02 ± 0.09 1.21 ± 0.05 3.15 ± 0.10 1.17 ± 0.05
B-c 3.03 ± 0.08 1.09 ± 0.03 2.94 ± 0.10 1.15 ± 0.05 3.06 ± 0.09 1.24 ± 0.06
B-o 3.13 ± 0.11 1.07 ± 0.04 3.16 ± 0.09 1.18 ± 0.05 3.21 ± 0.09 1.09 ± 0.06
p 0.196 0.163 0.344 0.226 0.189 0.062
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with the stress reaction and other simulations of fetal
lambs.
It is encouraging to observe the beneficial effects of
IDM/DXS on the gestational outcome after IUBAV op-
eration. However, there is still about 12.5% of preterm
birth in our model, suggesting that IDM/DXS adminis-
tration is still not sufficient to prevent all preterm birth
following the IUBAV. Other potential causes of preterm
birth remain to be identified and corrected. Asymptom-
atic infection may be a concern, which could be treated
with antibiotics. In addition, we do not know if IUBAV
could cause the fluctuation of progesterone level, which
may be corrected by progesterone. Therefore, in addition
to IDM/DXS, other tocolytics may also be useful to
completely control the preterm delivery following the
IUBAV. However, it should be cautious in evaluation of
the side effects in both mother and fetus. For example,
β2-agonist (such as Terbutaline and Ritodrine) and cal-
cium blocker (Nifedipine) have been used for tocolytics,
but they may complicate the cardiac conditions in fetus
receiving the IUBAV.
Of note, the current study has some limitations and
several questions still need to be answered. First, to
avoid the additional stimulation of control fetus, we did
not collect blood samples from the un-operated control
fetuses. As a result, we could not compare all of the
measurement results between operated and control
fetuses at the time of IUBAV completion. In addition,
because our primary goal for this study was to control
the preterm with all possible approaches, we used com-
binatorial treatment of IDM and DXS. Thus far, we can-
not differentiate the specific effects of IDM from that of
DXS on the overall beneficial outcomes in this model.
Whether one of the two agents is sufficient to achieve
the effects observed in the current study is still unclear.
Also, as we discussed above, application of additional
tocolytics is necessary to completely control preterm de-
liver following IUBAV. Lastly, the protocol used in this
goat model is similar to the one used for human, but the
species difference and the twin-gestational models
should be taken into consideration when the results are
applied to predict human typical singleton-gestation
situation.
Conclusion
In summary, the administration of IDM/DXS signifi-
cantly reduces stress response during and after the oper-
ation of IUBAV in experimental goats, and this therapy
may be valuable in controlling the preterm birth follow-
ing this intervention in human patients.
Abbreviation
IUCI: Intrauterine cardiac intervention; S/D: Ratio of peak blood flow between
systolic and diastolic phase; LVSP: Left ventricular systolic pressure;
IUBAV: Intrauterine balloon aortic valvuloplasty; BAV: Balloon aortic
valvuloplasty; BPD: Biparietal diameter; FL: Femur length; HR: Heart rate;
LV: Left ventricle; IDM: Indomethacin; DXS: Dexamethasone;
NE: Norepinephrine; BW: Body weight; COX: Cyclooxygenase;
PG: Prostaglandin.
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